The Cooper Companies (COO)
(Delayed Data from NSDQ)
$93.33 USD
+0.64 (0.69%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $93.32 -0.01 (-0.01%) 5:16 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.33 USD
+0.64 (0.69%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $93.32 -0.01 (-0.01%) 5:16 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
What's in Store for DENTSPLY (XRAY) This Earnings Season?
by Zacks Equity Research
DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?
by Zacks Equity Research
Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.
Why Is Cooper Companies (COO) Down 10.1% Since its Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why The Cooper Companies (COO) Might Surprise This Earnings Season
by Zacks Equity Research
The Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?
by Zacks Equity Research
CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.
DaVita (DVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.
Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?
by Zacks Equity Research
DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) Specialty Health unit is likely to drive the company's top line in the third quarter of fiscal 2018.
H&R Block (HRB) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Core business focus is likely to drive H&R Block's (HRB) Q2 earnings although macroeconomic challenges remain impediments
Will CooperVision Drive Cooper Companies' (COO) Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fourth quarter is expected to gain from strength in the CVI & CSI segments.
Only 4 Dental Stocks to Buy Amid MedTech Regulatory Woes
by Zacks Equity Research
After a stellar five-year run on the bourse, the performance of the dental industry has taken a hit in the last two years.
Patterson Companies (PDCO) Q2 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies' (PDCO) solid dental segment is a positive. The company anticipates troubles in its technology equipment business to persist through fiscal 2018.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.
What's in the Cards for LabCorp (LH) This Earnings Season?
by Zacks Equity Research
LabCorp (LH) might gain from continued growth in its companion diagnostics portfolio in Q3.
Will GNC Holdings (GNC) Disappoint This Earnings Season?
by Zacks Equity Research
Revenue growth at GNC Holdings (GNC) might remain sluggish on declining sales of protein, vitamins, weight management and food and drink categories in Q3.
Walgreens Boots (WBA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Walgreens Boots (WBA) may witness another quarter of prescription growth and strength in Retail Pharmacy USA division in Q4 earnings.
Why Is Cooper Companies (COO) Down 7.7% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Momentum Stocks to Pick Despite MedTech Policy Debacle
by Zacks Equity Research
Investors might pay heed to Zacks counsel and hitch the momentum ride to tide over the Obamacare debacle.
Dental Faces Regulatory Challenges: Only 5 Stocks to Pick
by Zacks Equity Research
Owing to the adversities in the medical universe, market watchers have adopted a bearish stance toward the dental space. These are the only five dental stocks that are expected to beat the ongoing MedTech gloom.
Top Ranked Momentum Stocks to Buy for September 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 8th:
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Why Is Cooper Companies (COO) Up 7.9% Since the Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can the Rally in Cooper Companies (COO) Shares Continue?
by Zacks Equity Research
Cooper Companies Inc (COO) has been on the move lately as the stock has risen by 17.1% in the past four weeks, and it is currently trading well above its 20-Day SMA